Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | RIN1 | Q13671 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 12/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6068512 | 0.76 | MAPT (0.35) | BACE1KDM4EXDH | |
| SCHEMBL6068516 | 0.75 | BACE1 (0.31) | BACE1XDH | |
| SCHEMBL31231913 | 0.74 | CYP3A4 (0.57) | BACE1CYP3A4BLMABL1RIN1 | |
| SCHEMBL4639744 | 0.71 | BACE1 (0.41) | BACE1KDM4E | |
| SCHEMBL15971206 | 0.71 | CYP3A4 (0.57) | BACE1CYP3A4BLMABL1RIN1 | |
| SCHEMBL2217785 | 0.70 | KDM4E (0.51) | BACE1CYP3A4BLMABL1RIN1 | |
| SCHEMBL2403638 | 0.69 | BACE1 (0.73) | BACE1CYP3A4BLMABL1RIN1 | |
| SCHEMBL11102202 | 0.69 | GAA (0.41) | — | |
| SCHEMBL1616242 | 0.69 | BACE1 (0.57) | BACE1CYP3A4BLMABL1RIN1 | |
| SCHEMBL6068563 | 0.68 | MAPK1 (0.48) | BACE1CYP3A4BLMABL1RIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318985-A1 | Novel 2-Aminopyrimidinone Or 2-Aminopyridinone Derivatives and Their Use | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318985-A1 | Novel 2-Aminopyrimidinone Or 2-Aminopyridinone Derivatives and Their Use | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318985-A1 | Novel 2-Aminopyrimidinone Or 2-Aminopyridinone Derivatives and Their Use | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| EP-1951682-A1 | NOVEL 2-AMINOPYRIMIDINONE OR 2-AMINOPYRIDINONE DERIVATIVES AND THEIR USE | Astra Zeneca AB (SE) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007058582-A1 | NOVEL 2-AMINOPYRIMIDINONE OR 2-AMINOPYRIDINONE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058582-A1 | NOVEL 2-AMINOPYRIMIDINONE OR 2-AMINOPYRIDINONE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
| US-7087614-B2 | Pyrimidine inhibitors of phosphodiesterase (PDE) 7 | BRISTOL-MYERS SQUIBB CO. (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1397142-A4 | PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7 | BRISTOL MYERS SQUIBB CO (US) | 2004-11-03 | — | — | EP | disclosed |
| EP-1397142-A2 | PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7 | Bristol-Myers Squibb Company (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20030162802-A1 | Pyrimidine inhibitors of phosphodiesterase (PDE) 7 | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-28 | — | — | US | disclosed |
| WO-2002102313-A2 | PYRIMIDINE INHIBITORS OF PHOSPHODIESTERASE (PDE) 7 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162802-A1 | Pyrimidine inhibitors of phosphodiesterase (PDE) 7 | PDE7A, PDE7B, PDE3A | BACE1 1389/4885CYP3A4 2363/4885BLM 1007/4885 |
| US-20080318985-A1 | Novel 2-Aminopyrimidinone Or 2-Aminopyridinone Derivatives and Their Use | PSEN2, PSEN1, GRIN2D | BACE1 12/4885CYP3A4 2496/4885BLM 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.